Stabilisation Notice - ASTRAZENECA

Societe Generale SA
29 July 2024
 

29th July 2024

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.


Astrazeneca

Pre-stabilisation Period Announcement

 

Societe Generale (contact: Nicole Bezzant +44 20 7676 6887) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance with [Commission Delegated Regulation (EU) 2016/1052 under the Market Abuse Regulation (EU/596/2014)][and] [the UK FCA Stabilisation Binding Technical Standards].

 

 

Securities


Issuer:

Astrazeneca

Guarantor(s) (if any):

N/A

Aggregate nominal amount:

EUR Benchmark

EUR Benchmark

Description:

Coupon:

Maturity:

Offer price:


 

Stabilisation:


Stabilisation Manager(s)

SG CIB

Stabilisation period expected to start on

29/07/2024

Stabilisation period expected to end no later than

04/09/2024

Existence, maximum size and conditions of use of overallotment facility:

The Stabilisation Manager(s) may overallot the securities to the extent permitted in accordance with applicable law.

 

In connection with the offer of the above securities, the Stabilisation Manager(s) may overallot10 the securities or effect transactions with a view to supporting the market price of the securities during the stabilisation period at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time11. Any stabilisation action or overallotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom12.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, [the UK] [any EEA Member State] before the publication of a prospectus in relation to the securities which has been approved by the competent authority in [the UK]  [that Member State] in accordance with Regulation (EU) 2017/1129 [as it forms part of domestic  law by virtue of the European Union (Withdrawal) Act 201813] (the "[EU][UK] Prospectus Regulation") [(or which has been approved by a competent authority in another Member State and notified to the competent authority that Member State in accordance with the EU Prospectus Regulation)], this announcement and the offer are only addressed to and directed at persons in [the UK]  [that Member State] who are qualified investors within the meaning of the [EU][UK] Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in [the UK] [that Member State]14.

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings